Introduction {#s1}
============

In medicine, gene therapy is defined as therapeutic strategy that transfers DNA to a patient's cells to correct a defective gene or a gene product in order to treat diseases that are not curable with conventional drugs ([@B121]). Direct *in vivo* administration of manipulated viral vehicle for gene delivery and *ex vivo* genetically engineered stem cells are the two principal approaches in advanced clinical gene therapy ([@B74]).

Over the last three decades, clinical gene therapy faced numerous obstacles and a great deal of failures, but it has now accomplished a huge progress in modern medicine and is finding its path into the clinic and the market ([@B59]), ([@B87]). In 2017, Luxurna, the first human gene therapy drug for an inherited retinal dystrophy, was approved by Food and Drug Administration () and entered the US market (Dias et al., 2017). In the same year, Kymriah and Yeskarta, two cell-based gene therapies for the treatment of acute lymphoblastic leukemia (ALL), were also approved by FDA ([@B32]; [@B211]). Various outstanding gene and cell-based gene therapies for both rare and common genetic disorders as well as life-threatening diseases, such as cancers and degenerative diseases, are in the evaluation phase prior to their translation into the clinic in the near future ([@B75]; [@B54]). 2017 marks an important year of gene therapy and is considered as a launch point for a new era of modern gene therapy.

In the present review, we summarize the history of development, mechanism-of-action (MOA), target indications as well as primary clinical trials of the twenty so-far approved human gene and cell-based gene therapy products. Additionally, their limitation, safety, manufacturing, dosage and sales are discussed ([**Figure 1**](#f1){ref-type="fig"}, [**Table 1**](#T1){ref-type="table"}).

![Approved human gene and cell-based gene therapy products. **(A)** *In vivo* approved gene therapy drugs such as Neovasculgen, Glybera, Defitelio, Rexin-G, Onpattro, Eteplirsen, Spinraza, Kynamro, Imlygic, Oncorine, Luxturna, Macugen, Gendicine, Vitravene as well as Zolgensma directly injected into their target tissue or organ. **(B)** *Ex vivo* gene therapy drugs include Zalmoxis as allogenic T cells, Invossaas allogenic chondrocytes, Yeskarta and Kymriahas autologous T cells (CAR T cell therapy), Strimvelisas autologous hematopoitic stem cells.](fgene-10-00868-g001){#f1}

###### 

History and featured data of twenty approved gene and cell based gene therapy products.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Product name                           Developer                                        Approval authority                                       Therapeutic indication and target tissue                                                                                                                                            Structure and mechanism of action                                                                                                                                             Dose                                                                                                                                                                 Limitations of use                                                                                          Price 2018/2019                                                                    Clinical trials ID     Key publication
  -------------------------------------- ------------------------------------------------ -------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- ---------------------- -------------------------------------------
  Fomivirsen (Vitravene)                 Isis Pharmaceuticals with Novartis Ophthalmics   USA FDA (1998)\                                          Treatment of CMV retinitis\                                                                                                                                                         ASO\                                                                                                                                                                          330 mg intravitreal injection on day 1 and day 15 of treatment for induction, then 330 mg monthly                                                                    Not recorded                                                                                                withdrawn                                                                          NCT00002187\           [@B85], [@B102], [@B103], [@B96]
                                                                                          EMEA\                                                    -eye                                                                                                                                                                                -inhibition of immediate-early IE-2 protein                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       NCT00002156\           
                                                                                          (1999)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT00002356\           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT00002355            

  Gendicine                              Shenzhen SiBionoGeneTech\                        China FDA (2003)                                         Head and neck squamous cell carcinoma (HNSCC)                                                                                                                                       Adenovirus contains wild-type p53.P53 production in cancer cells and inhibition of cell proliferation and induce apoptosis.                                                   1.0 × 10^12^vector particles per vial                                                                                                                                Women at pregnant or during breast-feeding period.\                                                         \$387 per injection                                                                ChiCTR-TRC-08000094\   [@B127]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Patients with generalized infection and fever of inflammation                                                                                                                                  ChiCTR-TRC-08000092\   [@B222]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ChiCTR-TRC-08000091    

  Pegaptanib (Macugen)                   Eyetech Pharmaceuticals and Pfizer. Inc          USA FDA\                                                 Treatment of neovascular age-related macular degeneration\                                                                                                                          Polynucleotide aptamer\                                                                                                                                                       0.3 mg once every 6 weeks by intravitreal injection                                                                                                                  Need for repeated and frequent intravitreal injection                                                       \$765 per dose                                                                     NCT00858208\           [@B100], [@B62], [@B16]
                                                                                          (2004)                                                   - eye                                                                                                                                                                               - inhibition VEGF165 isoform                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT01245387\           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT00788177\           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT00549055\           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT00460408\           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT00787319\           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT00312351\           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT00327470\           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT01712035            

  H101 (Oncorine)                        Shanghai Sunway Biotech\                         China FDA\                                               Patients with last stage refractory nasopharyngeal cancer(Head and neck cancer), NSCLC lung cancer, Liver cancer, malignant pleural and peritoneal effusion and pancreatic cancer   E1B-55 kDa gene-deleted replication-selective adenovirus                                                                                                                      Intratumoral injected at the dose of 1-3 vials per day, combined with 5-FU and cisplatin                                                                             Self-relieving local injection, mild to medium grade fever and influenza-like symptoms                      --\                                                                                NCT02579564\           [@B157]\
                                                                                          (2005)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               [@B218]

  Rexin-G                                Epeius Biotechnologies\                          Philippine FDA (2007)\                                   metastatic solid tumours(pancreatic cancer, Breast cancer, Osteosarcoma, Sarcoma)                                                                                                   Retroviral vector contains cyclin G1. Causes cell death by blocking the cell cycle event in G1 phase and promoting apoptosis in cancer cells                                  5 × 10^9^ (cfu)/ml                                                                                                                                                   Pregnant or nursing women\                                                                                  \$5000 per bag\                                                                    NCT00505271\           ([@B38]) ([@B98])
                                                                                          USA FDA\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Fertile patients                                                                                            500,000 \$\                                                                        NCT00572130\           
                                                                                          (2010)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      per treatment                                                                      NCT00505713\           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT00504998\           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT00121745            

  Neovasculgen (Pl-VEGF165)              Human Stem Cells Institute\                      Russian Ministry of Healthcare\                          Atherosclerotic Peripheral Arterial Disease (PAD), including Critical Limb Ischemia (CLI)\                                                                                          Plasmid DNA encoding the 165-amino-acid isoform of human vascular endothelial growth factor (pCMV - VEGF165)                                                                  1.2 mg per injection (totally 2.4 mg)\                                                                                                                               Not recorded                                                                                                \$6600 for treatment course                                                        NCT03068585\           ([@B69])\
                                                                                          (2012)                                                   intramuscular transfer (calf muscles)                                                                                                                                                                                                                                                                                                                             In 2 ml injection water\                                                                                                                                                                                                                                                                                                                                            NCT02538705\           [@B69]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Each injection at 4-5 sites at calf muscles                                                                                                                                                                                                                                                                                                                         NCT02369809            [@B68]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                [@B136]

  Alipogenetiparvovec (Glybera)          Amsterdam Molecular Therapeutics                 European Commission (EC)\                                Familial LPLD,\                                                                                                                                                                     AAV1- contains the human lipoprotein lipase (LPL) gene variant LPL^S447X^                                                                                                     1×10^12^gc/kg                                                                                                                                                        higher risk of bleeding and muscle disease in patients with immunodeficiency                                over \$1.2 m per patient                                                           NCT02904772\           [@B30]\
                                                                                          (2012)                                                   Leg muscle                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            NCT03293810            [@B79]

  Mipomersen, (Kynamro)                  ISIS Pharmaceuticals                             USA FDA\                                                 Treatment of homozygous familial hypercholesterolemia\                                                                                                                              ASO - Inhibition of the synthesis of apoB100                                                                                                                                  200 mg once weekly subcutaneous injection                                                                                                                            It is not established in patients with hypercholesterolemia and without HoFH                                \$6910\                                                                            NCT00607373\           [@B184]
                                                                                          (2013)                                                   - Liver, hepatocytes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               For 1-ml vial                                                                      NCT00280995\           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT00477594\           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT00694109            

  Imlygic                                Amgen                                            USA FDA\                                                 Multiple solid tumors\                                                                                                                                                              HSV-1oncolytic virus with deletions in the γ34.5 and α47 regions, which GM-CSF gene inserted into the deleted γ34.5 loci. Tumor Lysis and induce antitumor immune responses   10^6^-10^8^\                                                                                                                                                         Pregnancy, Immunocompromised Patients                                                                       \$65000 per treatment                                                              NCT02014441\           [@B111]\
                                                                                          (2016)                                                   (Melanoma, Pancreatic Cancer)                                                                                                                                                                                                                                                                                                                                     PFU/ml                                                                                                                                                                                                                                                                                                                                                              NCT01740297\           [@B187]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT02366195\           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT00402025            

  Eteplirsen (Exondys 51)                Sarepta Therapeutics                             USA FDA\                                                 Treatment of Duchenne muscular dystrophy\                                                                                                                                           PhosphomorpholidateMorpholino Oligomer (PMO)\                                                                                                                                 30 mg/kg once weekly by IV infusion                                                                                                                                  Not recorded                                                                                                \$1678\                                                                            NCT02420379\           [@B118]\
                                                                                          (2016)                                                   -Striated muscles                                                                                                                                                                   -Exon skipping                                                                                                                                                                                                                                                                                                                                                                                                                                                 For 2 ml vial                                                                      NCT01540409\           [@B53], [@B144], [@B94]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT01396239\           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT00844597\           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT02286947\           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT03218995\           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT02255552\           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT00159250            

  Spinraza (nusinersen)                  Biogen\                                          USA FDA\                                                 spinal muscular atrophy (SMA)/motor neurons and CNS                                                                                                                                 A modified 2'-O-2-methoxyethyl phosphorothioat ASO                                                                                                                            12 mg\                                                                                                                                                               Safe\                                                                                                       \$125000 per injection                                                             NCT01494701\           [@B82]\
                                         Ionis Pharmaceuticals, Inc.                      EMA\                                                                                                                                                                                                                                                                                                                                                                                                                       intrathecally                                                                                                                                                        Lumbar puncture complications\                                                                                                                                                                 NCT01780246\           [@B146]\
                                                                                          (2016)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Intestinalproblerms\                                                                                                                                                                           NCT02052791\           [@B83]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Respiratory complications                                                                                                                                                                      NCT01703988\           [@B21]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT02292537\           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT02193074\           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT02594124            

  Defibrotide (defibrotide sodium)       Jazz Pharmaceuticals plc                         USA FDA\                                                 SOS/VOD with multi-organ dysfunction                                                                                                                                                Single-stranded oligodeoxyribonucleotides                                                                                                                                     4 doses per day (every 6 h) of 6.25 mg/kg\                                                                                                                           Hemorrhage\                                                                                                 \$825 per 200-milligram or 2.5-milliliter vial                                     NCT00003966\           [@B57], [@B56]\
                                                                                          EMA\                                                                                                                                                                                                                                                                                                                                                                                                                       2-h Infusion                                                                                                                                                         Hypersensitivity Reactions\                                                                                                                                                                    NCT00628498\           [@B172], [@B174], [@B173]
                                                                                          (2016)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Fertility, Pregnancy                                                                                                                                                                           NCT00358501\           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT00272948            

  Luxturna (VoretigeneNeparvovec-rzyl)   Novartis Inc.                                    FDA\                                                     Inherited Retinal Dystrophies (IRD),\                                                                                                                                               AAV2 is laboring a normal copy of the RPE65 gene                                                                                                                              0.3 ml/eye                                                                                                                                                           Conjunctival hyperemia, cataract, increased intraocular pressure and retinal tear, holes,and inflammation   \$850000 or \$425000 per eye                                                       NCT00999609\           [@B148]\
                                                                                          (2017)\                                                  retinal pigment epithelial (RPE) cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                NCT03602820            [@B183]
                                                                                          EMA\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                          (2018)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Patisiran\                             Alnylam Pharmaceuticals Inc.                     FDA\                                                     Familial amyloid polyneuropathy (FAP), Liver, Peripheral nerves Heart, Kidney, Gastrointestinal tract                                                                               dsRNA encapsulated in aliposome                                                                                                                                               0.3 mg/kg every 3 weeks (24 weeks)                                                                                                                                   Infusion-related reactions (IRRs)                                                                           \$345000 per\                                                                      NCT01559077\           [@B7]\
  (Onpattro)                                                                              EMA\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        2 mg/ml                                                                            NCT01617967\           [@B8]\
                                                                                          (2018)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT01961921\           [@B196]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT01960348            

  Zolgensma\                             AveXis/\                                         USA FDA\                                                 Pediatric individuals less than 2 years of age diagnosed with SMA having bi-allelic mutations in SMN1 gene                                                                          Non-replicating rAAV9 containing cDNA of the human SMN gene under the control of CMV enhancer/chicken-β-actin-hybrid promoter                                                 A sterile solution of 2.0 x 10e13 vector genomes (vg)/ml\                                                                                                            The use of the dug in patients with advanced SMA Not recorded                                               Range (\$2.125-5.0M/treatment), the average lifetime cost/patient is \$4.2--6.6M   NCT03421977\           [@B10], [@B168], [@B64], [@B212], [@B137]
  (onasemnogene abeparvovec-xioi)        Novartis                                         (2019)                                                                                                                                                                                                                                                                                                                                                                                                                     \[1.1×10e14 vg/kg (body weight)\] by intravenous infusion                                                                                                                                                                                                                                                                                                           NCT03505099\           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT02122952\           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT0330627\            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NCT03461289            

  Strimvelis\                            GlaxoSmithKline (GSK)                            EMA\                                                     ADA-SCID                                                                                                                                                                            Autologous HSC expressing ADA - retroviral vector transduced                                                                                                                  2-20 million CD34+ cells per kg should be administered only once                                                                                                     Limitation of use in HCV infected patients (\> 15 IU/ml nucleic acid test)                                  594,000 euros, or \$648000\                                                        NCT00598481            [@B50]\
  (GSK2696273)                                                                            (2016)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      3 may 2017                                                                                                [@B9]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                [@B51]

  Zalmoxis                               MolMed SPAA                                      EMA\                                                     Hematopoietic Stem Cell Transplantation Graft vs Host Disease                                                                                                                       Allogenic T cell expressing HSV-TK suicide gene- retroviral vector transduced                                                                                                 1 ± 0.2 x 107 cells/kg infusion 21-49 days from transplantation, in the absence of GVHD. repeated every month (max 4 times) to reach the ≥100 T cell count per µl.   Not used in children or T cell ≥100/µl in circulation                                                       €149000\                                                                           TK007\                 [@B70]\
                                                                                          (2016)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Dec 2017\                                                                          TK008                  [@B52]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      €163900 EUR in Germany: ex-factory price                                                                  [@B207]

  Kymriah (Tisagenlecleucel CTL019)      Novartis Pharmaceuticals Corporation             USA FDA\                                                 Patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse                                                                           Autologous CART cell targeting CD19- Lentiviral vector transduced                                                                                                             0.2-5 x 106 CAR-positive viable T cells per kg for \<50kg patients or 0.1-2.5 x 108/kg for \>50kg cases                                                              lymphodepleting chemotherapy pretreatment is needed\                                                        \$475000\                                                                          NCT02435849\           [@B186]\
                                                                                          (2017)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Not indicated for treatment of primary CNS lymphoma                                                         Feb 2018                                                                           NCT02445248            [@B139]

  Yescarta (Axicabtageneciloleucel)      Kite Pharma, Incorporated                        USA FDA\                                                 Non-Hodgkin lymphoma. B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma                                                                       Autologous CAR T cell targeting CD19 -Retroviral vector transduced                                                                                                            2 × 106 CAR-positive viable T cells per kg                                                                                                                           lymphodepleting chemotherapy pretreatment is needed\                                                        \$373000\                                                                          NCT02348216            [@B177]\
                                                                                          (2017)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Not indicated for treatment of primary CNS lymphoma                                                         April 2018                                                                                                [@B130]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                [@B156]

  INVOSS\                                TissueGene (now called KolonTissueGene)          South Korea's Ministry of Food and Drug Safety (MFDS)\   Kellgren-Lawrence Grade 3 knee osteoarthritis (OA)\                                                                                                                                 Retrovirally transduced allogenicchondrocytes that upregulates TGF β1                                                                                                         1.8x10^7^ cells per 3 ml (mixture of transduced and non-transformed chondrocytes)                                                                                    Peripheral edema\                                                                                           Not recorded                                                                       NCT01221441\           [@B45]\
  (TissueGene-C or Tonogenchoncel-L)                                                      (2017)                                                   intra-articular space of the knee via X-ray guidance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   arthralgia\                                                                                                                                                                                    NCT03412864            [@B41]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          joint swelling\                                                                                                                                                                                                       [@B46]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Injection-sitepain                                                                                                                                                                                                    [@B124]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Human Gene Therapy Products {#s2}
===========================

Vitravene (Fomivirsen) {#s2_1}
----------------------

Vitravene, also called as Fomivirsen is an antisense oligonucleotide (ASO) designed as a therapeutic strategy for cytomegalovirus (CMV) retinitis in HIV-positive patients who have not an option for CMV retinitis treatment ([@B15]; [@B11]). Fomivirsen is the first ever gene-silencing antisense therapy approved for marketing by the FDA. This drug was developed through collaboration between Isis Pharmaceuticals and Novartis Ophthalmics and was approved by FDA in August of 1998 and 1 year later by EMEA (European Agency for the Evaluation of Medicinal Products) to treat cytomegalovirus retinitis ([@B65]).

CMV retinitis, a serious viral eye infection of the retina in patients affected by AIDS, is estimated to affect 30% of these patients. Risk of AIDS-related CMV retinitis is almost always directly correlated with lower CD4 counts (less than 200 cells/µL) and lower peripheral-blood absolute CD4 lymphocyte counts (50 cells/µL or less) ([@B89]; [@B195]).

Fomivirsen is a 21-base phosphorothioate oligodeoxynucleotide which has a CpG motif near its 5' terminal part. It specifically targets the IE-2 mRNA molecule which is encoding a protein required for CMV replication ([@B11]; [@B153]). The recommended dose of Fomivirsen is 330 mg intravitreal injection on day 1 and day 15 of treatment for induction, then it is continued 330 mg every 4 weeks. The most frequently observed adverse effects include ocular inflammation and increased intraocular pressure. Half-life clearance of the drug is approximately 55 h in humans vitreous body ([@B101]; [@B206]).

In clinical studies by Vitravene Study Group, *lesion activity* regressed in 80% of participants and also it became completely inactive in 55% of participants during Fomivirsen therapy. Different studies indicate that Fomivirsen can successfully ameliorate the symptoms of CMV retinitis ([@B101]; [@B102]; [@B103]; [@B206]).

The development of highly active anti-retroviral therapy (HAART) significantly decreased the CMV retinitis incidence by 55--95%. Therefore marketing of Fomivirsen stopped in Europe and the USA in 2002 and 2006 respectively, as a consequence of the low demand. According to the Novartis Ophthalmics, demand for Vitravene was less than 100 units per year ([@B66]; [@B208]; [@B116]).

Gendicine (rAd-p53) {#s2_2}
-------------------

Gendicine gene therapy drug is harboring Tp53 gene which has been developed to treat head and neck squamous cell carcinoma (HNSCC). This recombinant adenovirus was developed by Shenzhen SiBionoGeneTech and was approved by China Food and Drug Administration (*CFDA*) on October 16, 2003; and found its way to the commercial market in 2004 ([@B159]; [@B160]).

Inactivation of different tumor suppressors including: TP53, NOTCH1, CDKN2A, PIK3CA and FBXW7 have been reported in HNSCC. Cells harboring those inactivated proteins could divide without control resulting in cell immortalization and increased risk of malignant transformation ([@B67]; [@B158]).

In Gendicine drug, E1 region of human serotype 5 adenovirus (Ad5) has been replaced by human wild-type Tp53. The expression of Tp53 in cancer cells stimulates antitumor properties by initiating apoptotic pathways, suppressing DNA repair and anti-apoptotic events as well as seizing the survival pathways. ([@B214]). The vector is produced in HEK293 cells by co-transfection of the Tp53 expression cassette shuttle vector with an Ad5 genome recombinant plasmid. The cassette contains the Rous sarcoma virus promoter, the wild type human Tp53 gene and a bovine poly-A signal. Upon intratumor injection at a concentration of 1.0 × 10^12^ viral vector particles per vial, Gendicine binds to the coxsakievirus-adenovirus receptor and enters the tumor cells *via* receptor-mediated endocytosis, expressing ectopic Tp53 gene. The most common side effect with Gendicine is self-limiting fever of 37.5°C to 39.5°C which occurs usually 2 to 4 h after administration lasting for approximately 2 to 6 h ([@B40]; [@B127]; [@B222]).

The initial clinical trial of Gendicine drug was done in four hospitals of Beijing city between 1998 and 2003 years ([@B105]; [@B214]). Also, from 2003 to 2012, totally 16 human clinical studies were carried out for treatment of advanced stages and grades of head and neck cancer, malignant glioma, ovarian cancer, and hepatic cell carcinoma. Treatment with Gendicine resulted in a better overall response and higher survival rate compared to control groups ([@B39], [@B220]).

In a clinical study with patients suffering from nasopharyngeal cancer, administration of Gendicine in combination with radiotherapy resulted in higher survival rates compared to control groups ([@B221]). A clinical trial reported that administration of Gendicine and chemotherapeutic drugs can significantly improve survival rate more than either chemotherapy-only or gene therapy-only groups in patients of advanced oral squamous cell carcinoma ([@B133]; [@B221]).

Macugen (Pegaptanib) {#s2_3}
--------------------

*Pegaptanib* was developed by *Eyetech Pharmaceuticals* and PfizerInc with brand name of Macugenis. It is a polynucleotide aptamer targeting vascular endothelial growth factor (VEGF165 isoform) for neovascular age-related macular degeneration (AMD) treatment. Pegaptanib was the first anti-angiogenic agent approved by the USA FDA in December 2004 and was the only therapy for treatment of AMD. It is also the first therapeutic aptamer with RNA structure achieving FDA market approval ([@B100]).

AMD is the most common cause of severe vision loss and blindness among the aged individuals in the developed world. It is characterized by deterioration of the central part of the retina ([@B216]). Due to abnormal growth of blood vessels it accounts for 90% of severe vision losses ([@B81]). It has been suggested that VEGF plays a prominent role in growth and permeability of new vessels in AMD. Anti-VEGF agents are molecular therapies which attempt to block angiogenesis as well as vessel permeability ([@B86]; [@B215]; [@B27]; [@B191]).

Pegaptanib is a 28-mer RNA oligonucleotide covalently linked to 2 branched 20-kD polyethylene glycol chains. It specifically binds to VEGF165 isoform at the heparin binding site; thus preventing its binding to VEGF receptors that are located on the vascular endothelial cells surface. VEGF165 has been implicated in pathological ocular neovascularization by increasing vascular permeability and inflammation ([@B181]; [@B178]). The recommended dose is 0.3 mg/90 µl of Pegaptanib administered once every 6 weeks by intravitreal injection into the eye. Based on preclinical data, Pegaptanib is metabolized by endo- and exonucleases and is not influenced by the cytochrome P450 system ([@B73]; [@B210]).

In two clinical trials involving totally 1186 participants, efficacy of Pegaptanib was determined by the ability of patients to lose less than 15 letters of visual acuity from baseline without dose--response. The result demonstrated that Pegaptanib is an effective therapy for AMD ([@B100]; [@B62]). Moreover, a clinical trial assessed the side effects and the efficacy of Pegaptanib in the treatment of 23 participants suffering from neovascular AMD with previous history of arterial thromboembolic events (ATEs). Pegaptanib did not reveal any systemic or ocular side effects nor did it lead to any recurrent ATEs ([@B16]).

By 2010, sales of Pegaptanib declined due to better visual outcomes obtained through aflibercept, ranibizumab and bevacizumab drugs which are attested to be less expensive and appeared to be more effective than Pegaptanib ([@B29]; [@B185]). Nevertheless, Pegaptanib still holds a relatively small market share for the treatment of AMD. Currently, Pegaptanib is marketed by Bausch and Lomb and it approximately costs \$765 per dose.

Oncorine (rAd5-H101) {#s2_4}
--------------------

As the first oncolytic virus approved by CFDA, recombinant human adenovirus type 5 (rAd5-H101) was commercially marketed under the brand name of Oncorine in November 2005 and was manufactured by Shanghai Sunway Biotech. It was initially licensed for the treatment of patients with last-stage refractory nasopharyngeal cancer in combination with chemotherapy following phase III of the clinical trial ([@B128]).

Loss of Tp53 gene function is linked with resistance to chemotherapy and reduced survival rate of patients affected by non-small cell cancers of the breast, colon, lung, head and neck as well as ovaries. Therefore TP53 is considered as promising target for gene therapy of NSCC derived cancers. The E1B-55 KD gene has been totally depleted in Oncorine adenovirus which is responsible for p53 inactivation. Selectively, Oncorine propagates in P53-deficient cancer cells while the adenovirus which lacks the E1b-55KD fails to replicate in normal cells. Following cancer cell lysis, adenoviruses releases and infects neighboring cells initiating a cascade of Oncorine-mediated cell cytotoxicity ([@B123]).

The first Oncorine clinical trial was carried out on 37 participants with recurrent head and neck carcinoma testing intratumoral and peritumoral injection. The findings were in favor of highly selective tissue destruction, significant tumor regression and no toxicity evidence to injected normal peritumoral tissues ([@B157]). Oncorine in combination with chemotherapy in participants with late stages and high grades of different cancers, is administered by intratumor injection. The findings exhibited potential anti-tumor property to refractory aggressive tumors in combined with chemotherapy with minimal toxicity and accepted tolerance of participants ([@B133]). A phase III clinical study was carried out on 160 participants with head and neck or esophagus squamous cell cancers. Intratumoral injection of Oncorine was fallowed with cisplatin plus 5-fluorouracil (PF) or adriamycin plus 5-fluorouracil (AF) regimen versus PF or AF regimen alone. The result demonstrated a distinct efficacy and relatively safety of the drug ([@B218]).

Following the successful phase III clinical trial, the process of commercialization of Oncorine was launched and its efficacy and safety was examined on other cancer types including colon cancer and non-small cell lung cancer (NSCLC) ([@B170]). Oncorine is not basically associated with major adverse effects except for self-limiting reaction to local injection, mild to moderate grade fever and influenza-like symptoms.

Rexin-G (Mx-dnG1) {#s2_5}
-----------------

Rexin-G is a retroviral vehicle harboring a cytocidal cyclin G1 construct and is considered the world's first tumor targeting injectable gene therapy vector approved by FDA for metastatic pancreatic cancer. The drug was officially approved by Philippine FDA in December 2007 resulting in progression of clinical studies to Phase III trials in the USA ([@B98]).

Rexin-G has a hybrid LTR promoter to express cyclin G1. The vector also comprises a neomycin resistance gene which is combined by the SV40 early promoter and is used for vector titer determination. Finally, the Rexin-G is produced by transient co-transfection of three separate vectors in 293T cells ([@B97]; [@B99]). Rexin-G triggers cell death and apoptosis (by suppressing the cell cycle in G1 phase) in cancer cells. Moreover, it is associated with neovasculature in preclinical studies ([@B99]; [@B38]).

The result from phase I/II trial of Rexin-G drug in participants with gemcitabine-resistant metastatic pancreatic cancer demonstrated it was well tolerated and safe. Also, elevated survival rate in patients was observed. Progressive clinical development of Rexin-G demonstrated the potential safety and efficacy of this gene therapy product for metastatic solid tumors that are resistant to standard chemotherapy ([@B99]; [@B38]).

Neovasculgen (Pl-VEGF165) {#s2_6}
-------------------------

In 2010, Human Stem Cell Institute of Russia developed Neovasculgen (PI-VEGF165), a plasmid DNA encoding VEGF 165 under the control of a CMV promoter for treatment of atherosclerotic Peripheral Arterial Disease (PAD). The drug was listed in Vital and Essential Drugs (EUVED) of Russian Ministry of Health in 2012 and was then distributed in the Russian market ([@B69]).

VEGF is a kind of angiogenic effector which triggers cellular proliferation and endothelial migration, angiogenesis as well as enhanced endothelial renovation. These events happen by inducing rapid secretion of nitric oxide and prostacyclin molecules from endothelium stimulating a vasculoprotective effect which is confirmed in some preclinical and clinical studies ([@B17]; [@B136]). Neovasculgen recombinant DNA is composed of a transcription start site, the encoding VEGF165 isoform, a polyadenylation signal, a splicing signal and SV40 transcription terminator ([@B24]).

The main and only phase 2b/3 multicenter clinical study of Neovasculgen was conducted on 75 patients with PAD. The intramuscular administration of the drug resulted in an increase of pain-free walking distance as well as a significant increase in ankle-brachial index (ABI) and blood flow velocity (BFV). Thus, it was introduced as an effective therapeutic strategy of medium to severe claudication or limping due to chronic lower limb ischemia. ([@B69]).

Moreover, an international post marketing surveillance study confirmed the safety and efficacy of Neovasculgen in 210 patients with PAD suggesting the absence of no adverse effects ([@B68]). Authorization of the drug has recently begun in Ukraine, European Medicines Agency (EMA). However, FDA have not yet evaluated or validated the drug probably due to low penetrance of the disease. Neovasculgen would cost nearly *\$*6,600 per treatment course.

Glybera (Alipogenetiparvovec) {#s2_7}
-----------------------------

Alipogenetiparvovec, marketed as Glybera, is a gene therapy drug for Lipoprotein Lipase Deficiency (LPLD) treatment. It was developed by Amsterdam Molecular Therapeutics (AMT) in April 2012. In October 2012, the European Commission (EC) approved UniQure as a marketing authorization of Glybera for treating LPLD. Glybera is the first licensed gene therapy product for an inherited disorder in Europe ([@B30]). However, given the lack of an appropriate relationship between supply and demand, it was declared a halt to Glybera marketing authorization in Europe in April 2017 ([@B104]).

Familial LPLD is an autosomal recessive genetic disorder caused by loss-of-function mutations in LPL gene encoded lipoprotein lipase enzyme. Lack of the enzyme results in LPLD leading to improper digestion of certain fats and massive accumulation of fatty droplets ([@B78]). Glybera contains LPL gene variant cassette of LPL^S447X^ in a viral vector. The vector consisted of a protein shell part derived from adeno-associated virus serotype I (AAV1), the CMV promoter, a woodchuck hepatitis virus post-transcriptional regulatory element flanked by AAV2 derived inverted terminal repeats (ITRs). Furthermore, recombinant baculovirus technology was used for the Glybera production ([@B92]). Each vial of Glybera comprises of 3 × 1,012 genomic copies of alipogene tiparvovec (AAV1-LPL^S447X^) in 1 ml of a phosphate-based formulation buffer containing 5% sucrose ([@B20]). Increased level of creatine kinase in the blood is observed following Glybera injection and it also increased the risk of bleeding and muscle disease in patients with immunodeficiency ([@B79]).

In a clinical trial, 22 subjects were recruited and injected with Glybera; 7 cases demonstrated a decreasing in median plasma triglyceride (TG) by at least 40% over 3 and 12 weeks involvement. The duration of Glybera efficacy did not rise by the immune suppression ([@B81]; [@B91]). However, in the high-dose cohort, VLDL, total cholesterol and TG content in the VLDL segments were increased at 12^th^ and 52^nd^ weeks post injection. Accordingly, there was a consistent rise in plasma LPL activity despite lack of prolonged effect on total plasma TG and chylomicron metabolism modifications ([@B13]). In another clinical trial, there was a single group assignment which enrolled five patients with LPLD. TG concentrations decreased in 12 weeks upon treatment. Also, reduction in chylomicrons was observed ([@B176]). EC approval for Glybera was based on the results obtained from three Phase III clinical trials conducted in Canada and the Netherlands. Results from 27 patients with LPLD demonstrated that Glybera was well approved in all three clinical trials and no crucial safety signals were noticed. The one-time Glybera administration reduced the frequency of acute pancreatitis ([@B93]).

Glybera, one the highest-priced drug in the world, over \$1.2 million per patient, has been withdrawn from the market because it has turned out to be a commercial loser. Some reporters declared that the drug has only been paid for once since its launch in 2017 ([@B86]).

Kynamro (Mipomersen) {#s2_8}
--------------------

Mipomersen, with a market name of Kynamro, is useful as an adjunct therapy for homozygous familial hypercholesterolemia (HoFH) ([@B166]; [@B140]; [@B193]; [@B200]). Mipomersen was developed by Ionis Pharmaceuticals as a novel ASO inhibitor for the cure of HoFH ([@B60]). It was rejected by EMA in 2012 due to cardiovascular and liver adverse effects ([@B135]). However, in January 2013, the USA FDA granted approval on its marketing as an orphan drug for the management of HoFH ().

FH is an autosomal dominant genetic disorder caused by mutations in genes of low-density lipoprotein receptor (LDL-R), apolipoprotein B (ApoB) and pro-protein convertase subtilisin/kexin type 9 (PCSK9). *APOB* gene encodes APOB protein that it is critical for LDL production and delivery ([@B95]; [@B165]; [@B109]).

Mipomersen is an ASO that interfere with the synthesis of ApoB. Mipomersen contains 20 nucleotides that binds to the coding region of the ApoB mRNA in a sequence-specific manner. Thus, it resulted in RNase H-mediated disruption of the mRNA molecule, thereby reducing synthesis of ApoB in the hepatocytes. Mipomersen decreases LDL-C, ApoB, total cholesterol (TC) and non-high- density lipoprotein cholesterol (non-HDL-C) in HoFH patients. Furthermore, Mipomersen causes a dose dependent decreasing of ApoB mRNA in the hepatocytes which is correlated with the reduction of ApoB -containing lipid particles in blood ([@B166]; [@B175]).

Mipomersen is typically administered at a dose of 200 mg subcutaneously once per week. Around 85% of the drug is bound by Albumin in plasma. Half-life time of the injected drug is approximately 2 to 5 h. In addition, the half-life of the drug in plasma and tissue is approximately 1 to 2 months ([@B126]). Mipomersen is metabolized and processed initially by tissue endonucleases to generate shorter oligonucleotides available for further metabolism by exonucleases. Due to the risk of hepatotoxicity, Mipomersen is used with caution when prescribed with other LDL-lowering or hepatotoxic medications ([@B180]; [@B61]).

Raul et al. conducted four different phase III trials in various populations of FH patients. The outcomes demonstrated that Mipomersen invariably reduced plasma Lp(a) levels by the 28^th^ weeks by an average of 26.4% compared with the placebo groups ([@B184]). In phase III clinical trials, the most (84%) commonly-reported adverse effects were injection site reactions including erythema and pruritus, influenza-like symptoms (30%) such as fatigue, pyrexia and chills as well as nausea (14%) ([@B166]; [@B193]). In a phase III trial, cardiac events were observed with a high significant frequency in the Mipomersen group in comparison to the placebo ([@B140]).

Due to the liver toxicity risk, Mipomersen is only used for patients under the constricted program called Kynamro^™^ Risk Evaluation and Mitigation Strategy. Single-use 1-ml vial of Mipomersen with a concentration of 200 mg/ml is available ([@B184]). The average price for 1 week of therapy with the drug is \$6910. Nevertheless, due to adverse events, serious liver toxicity and reactions at injection site, a large proportion of patients discontinued the drug within 2 years.

Imlygic (Talimogenelaherparepvec) {#s2_9}
---------------------------------

Imlygic or Talimogenelaherparepvec is a genetically manipulated oncolytic herpes simplex virus type 1 (HSV) that is developed to be used against multiple solid tumors such as unresectable cutaneous, subcutaneous and nodal lesions of melanoma ([@B35]). Imlygic was created by BioVex Inc. under the brand name of OncoVEX^GM-CSF^. The drug was approved by the USA FDA in October 2015 for targeting melanoma. It was subsequently approved in Europe and Australia in 2016 ([@B169]; [@B163]; [@B35]).

Imlygic is an advanced-generation of double-manipulated HSV-1 oncolytic virus with depletions in the γ34.5 and α47 segments, which has been replaced by the human granulocyte-macrophage colony-stimulating factor (GM-CSF) gene ([@B119]). The γ34.5 region deletion is mainly accounted for cancer-selective proliferation and reduction of pathogenicity. The γ34.5 gene plays a role in inhibiting protein synthesis of host cell upon viral infection. Thus suppressing γ34.5 seizes the virus replication in healthy cells. In cancer cells, γ34.5-deficient HSV-1 can still propagate ([@B112]; [@B119]). The α47gene functions to antagonize the host cell transporter associated with antigen presentation. Consequently, the depletion of the gene results in reducing of MHC class I regulation and expression, which enhances the activities of antitumor immune responses. Moreover, two copies of the human GM-CSF gene are incorporated into the virus under the control of the CMV promoter providing high levels of gene expression. Local GM-CSF production by Imlygic is responsible for stimulating the immune system responses ([@B23]).

Imlygic drug is sold as a sterile, preservative-free solution for intralesional injection, developed at a formal concentration of either 10^6^ or 10^8^ plaque-forming units (*PFU*)/ml. Patients receive the drug on days 1 and 15 of each 28-day period for 24 weeks intervention. Each dose should be injected into cutaneous, subcutaneous, and/or nodal lesions that are visible, palpable or detectable by ultrasound guidance. ([@B88]).

Harboring a herpes virus, Imlygic could be reactive at a later time point, making herpes infections such as cold sores. Imlygic could cause more extensive medical conditions and side effects in patients with impaired immune system (e.g. HIV infected). ([@B164]; [@B88]).

In several clinical trials, it has been observed that intralesional administration of Imlygic improves immunological response and causes regression in injected lesions ([@B111]). An analysis of phase II clinical trial outcomes revealed that Imlygic exerted a clear oncolytic effect on injected tumors as well as a secondary immune response as anti-tumor effect on non-injected lesions. Thus, it paved the path for initiation of the phase III of the drug ([@B187];[@B114]). In phase III trial, Imlygic significantly improved durable response rate versus GM-CSF in 436 patients with unresectable advanced-stage melanoma. ([@B14]).

Exondys 51 (Eteplirsen) {#s2_10}
-----------------------

Eteplirsen, was developed by Sarepta Therapeutics under the *trade name of Exondys 51. This drug is* a 30-mer Phosphomorpholidate Morpholino Oligomer (PMO) designed to cause depletion of exon 51 of dystrophin gene. Expression of functional dystrophin protein in patients with duchene muscular dystrophy (DMD) who have mutated DMD gene is amenable by skipping exon 51 ([@B120]; [@B192]). This group of patients cover approximately 13% of all DMD cases, making exon 51 a suitable target for gene targeting ([@B129]). *I*n September 2016, USA FDA approved Exondys 5 in an accelerated procedure based on the production of dystrophin in skeletal muscle found in some cases treated with the drug. ([@B203]; [@B12])

DMD is a severe X-linked genetic disorder causing a degenerative muscle atrophy and early death. The worldwide incidence is estimated with 1/5000 male births ([@B143]; [@B149]). The disease results from absence of the membrane-associated protein dystrophin, which renders a structural base connecting the cytoskeletal actin in muscle fibers to the extracellular matrix environment ([@B76]). The DMD gene encoding for dystrophin consists of 79 exons spread over 2.4 Mb region. Exon deletions that occurs more commonly in exons 47 to 63, derange the reading frame of the dystrophin mRNA molecule. This could result in losing protein synthesis in the striated muscle ([@B118]).

Eteplirsen targets exon 51 in the dystrophin immature RNA (hnRNA) in DMD patients who carry a deletion between the terminus of exon 50 and the beginning of exon 52 comprising deletion of exons 45--50, 47--50, 48--50, 49--50, 50, 52 or 52--63. Then, the splicing machinery excludes the problematic exon from the final transcript, resulting in production of a shortened functional dystrophin protein ([@B118]; [@B192]). Lack of charge and no interaction with nucleases have turned Eteplirsen into a highly stable and safe therapeutic drug. Lower protein interaction provides the drug insufficiently activate innate immune response ([@B197]; [@B152]).

*Exondys*51 was evaluated in two phase I/II, four phases II and two phase III clinical studies ([@B53]; [@B31]; [@B94]; [@B141]). Results from a confirmatory phase III trial comprising two 80-patient cohorts were required by the FDA to obtain the final approval. After 1 year of treatment, a significant average increase in dystrophin protein levels was seen at 0.22--0.32% of normal levels status. Taken together, clinical studies provided evidence that *Exondys*51 causes exon skipping, muscle cell penetration and induction of novel dystrophin synthesis. While *Exondys*51 is now available to applicants, further clinical trials are still required by the FDA to support the clinical benefit of the drug; 2 ml vial (50 mg/ml) of Exondys51 cost around \$1,678 and the average price per patient of the drug stands at *\$300,000* annually. ([@B12])

Spinraza (Nusinersen) {#s2_11}
---------------------

Nusinersen, commercialized under the name of Spinraza by Biogen, was the first ever medication approved for treatment of spinal muscular atrophy (SMA). Nusinersen was approved by USA FDA in December 2016 and by EMA in May 2017 ([@B90]).

SMA is a rare but one of the most common autosomal recessive disorder indicated by progressive disruption of motor neurons of the anterior horn of the spinal cord ([@B162]). Deficiency in the survival motor neuron (SMN) protein is the molecular basis of the disorder ([@B125]). As an evolutionarily-conserved protein, SMN is encoded by SMN1 and SMN2 genes and is critical for transcriptional regulation, telomerase regeneration and cellular trafficking of motoneurons ([@B189]). Deletion mutations (particularly in exon 7 and 8) in telomeric copies of the SMN1 gene have been observed in approximately 95% of SMA patients ([@B198]). According to the well-defined underlying mechanism of SMA, several genetic-based therapeutic procedures have been defined which primarily aimed to increase the accessibility of SMN protein in motor neurons ([@B63]). These approaches included SMN1 gene replacement ([@B132]), SMN2 alternative splicing modulation ([@B219]), SMN2 gene activation by previously approved drugs such as Salbutamol ([@B147]), Butyrates ([@B37]) and Valproic acid ([@B28]), SMN stabilization ([@B138]), neuroprotection ([@B113]), as well as stem cell-based therapies ([@B145]).

Nusinersen (Spinraza) is an ASO which targets intron 7 on the SMN2 hnRNA ([@B34]; [@B55]), modulating alternative splicing by increasing inclusion of exon 7 in the final processed RNA. This results in higher levels of functional SMN protein in central nervous system (CNS) ([@B219]; [@B58]).

Nusinersen is administered intrathecal while performing lumbar punctures under direct supervision of a healthcare professional ([@B42]). Following the administration of Nusinersen, it is distributed from the site of injection to motor neurons, vascular endothelial cells as well as glial cells in the CNS tissue ([@B82]). The safety and/or tolerability profile of Nusinersen was acceptable in patients with SMA participating in several clinical trials ([@B82];[@B21];[@B83]; [@B146]). Yet, the most frequently observed adverse effects of the drug were respiratory complications and elevated urine protein levels ([@B83]). Moreover, intrathecal administration limits the treatment to CNS which is crucial for motoneurons but does not target other disorders in the heart, liver, pancreas, intestine and lung organs in SMA patients ([@B188]). As such, an optimal treatment to restore SMN protein in peripheral tissues is also needed.

Several therapeutic phase I, II, and III clinical trials demonstrated promising findings and significant improvements in motor milestones ([@B110]). Nusinersen was initially approved on 23 December, 2016 for treatment of the SMA in pediatric and adult patients in USA and is currently in the market. However, Spinraza is belongs to one of the most expensive drugs in the world with the price of \$125000 per injection ([@B134]). Although Spinraza expenses is supported by some health insurance providers in USA and France, Germany, Iceland, Italy and Japan, this expensive drug is not funded in other territories.

Defitelio (Defibrotide) {#s2_12}
-----------------------

Defibrotide, commercially known as Defitelio, is manufactured by Jazz Pharmaceuticals plc. Defitelio is a DNA derivative anticoagulant used for patients with hepatic sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) with renal or pulmonary dysfunction following the cytoreductive treatment prior to hematopoietic stem-cell transplantation (HSCT). The efficacy data coming from investigating 528 hepatic VOD participants with renal or pulmonary dysfunction following HSCT, supported approval of Defibrotide by USA FDA in March 2016 ([@B173]). It was also evaluated and approved by EMA in May 2017.

SOS/VOD is an lethal indication of the conditioning regimens for HSCT which is distinguished by harmful hepatomegaly, hyperbilirubinemia, quick weight gain and gathering of ascitic fluid within the stomach ([@B18]).VOD/SOS may also arise in patients treated by chemotherapy or calicheamicin--antibody drug conjugates ([@B151]).

Defibrotide as the only approved gene therapy drug accessible for SOS/VOD patients with multi-organ damage (MOD) following HSCT has been associated with promising effects in the United States and the European Union. Defibrotide is a combination of primarily single-stranded oligo DNAs obtained from porcine mucosa tissue by controlled depolymerization with aptameric function on the vascular endothelial cells. It has antithrombotic, thrombolytic, anti-inflammatory and anti-ischemic properties ([@B84]). Defibrotide is considered an adenosine receptor agonist as it has affinity for receptors A1 and A2 on the plasma membranes of the vascular endothelium ([@B22]). It was originally introduced as therapeutic strategy for thrombophlebitis, and as prophylaxis of deep vein thrombosis (DVT) in Italy ([@B171]).

Results of early clinical studies demonstrated promising response rates of 36--76% of Defibrotide in SOS/VOD with MOD ([@B172]; [@B48]; [@B57]; [@B174]). Based on the result of a phase II clinical trial, 25 mg/kg/day was considered as the Defibrotide dosage with a base duration of 21 days ([@B174]). Moreover, in a phase III trial, 356 pediatric participants at high risk of developing SOS/COD post-HSCT were involved to evaluate the prophylactic effects of Defibrotide. The result revealed a significant decreasing in SOS/VOD indication onset by Day +30 post-HSCT for the Defibrotide prophylaxis group in compared with control group ([@B56]).

However, several adverse side effects and reactions including coagulopathy, cerebral hemorrhage, hypotension, pulmonary hemorrhage, gastrointestinal hemorrhage and vomiting have been reported. Defibrotide was permitted marketing authorization by the EMA in October 2013 and FDA in March 2016 as the first approved therapeutic method for severe hepatic SOS/VOD post-HSCT indicated in adults and pediatric patients over 1 month of age. Defibrotide is an expensive DNA drug with a wholesale price of approximately \$825 per 200mg or 2.5milliliter vial (daily price for the medicine is \$7425 based on the recommended dose) ([@B36]; [@B194]; [@B209]).

Luxturna (Voretigene Neparvovec) {#s2_13}
--------------------------------

Voretigene Neparvovec-rzyl (AAV2-hRPE65v2), also called Luxturna which is developed and now available on the market by Spark Therapeutics. It is the first USA FDA-approved gene therapy drug for an inherited disease. Approval from FDA and EMA were granted on 19 December, 2017 and 23 November, 2018, respectively. Luxturna is applied intraocularly and is an orphan drug designated for the cure of inherited retinal dystrophy caused by bi-allelic RPE65 mutations ([@B167]). This form of inherited retinal dystrophies (IRD), leads to clinical phenotypes of leber congenital amaurosis type 2 (LCA2) and retinitis pigmentosa type 20 (RP20). The most common form of IRD is retinitis pigmentosa (RP) with the reported impact of 1 in ∼4000 individuals. Both LCA2 and RP20 are inherited in an autosomal recessive way. Due to biallelic mutations in the RPE65 gene, its isomerase deficiency destroys the ability of retinal pigment epithelium (RPE) cells to react to the light. Finally, the accumulation of toxic precursors resulted in RPE cells death, progressive visual exacerbation and total blindness ([@B49]; [@B148]).

Luxturna is applied by a subretinal injection following a vitrectomy where AAV2 targets RPE cells and brings in a normal copy of the RPE65 gene to compensate for the biallelic mutation. Resulting RPE65 protein acting as isomerohydrolase transforms the trans-retinyl esters to 11-cis-retinal, which is the natural ligand and chromophore of the opsins of rod and cones photoreceptors ([@B182]). In absence of functional RPE65, the opsins in not able to record light or transduce it into electrical responses to induce vision. Functional RPE65 protein resulted in the restoration of the visual cycle by regeneration of 11-cis-retinal (a critical visual pigment component) ([@B205]).

Safety and efficacy of Luxturna were examined in two clinical studies. Phase I trial was a dose-exploration safety study and phase III trial was an efficiency controlled study. 41 participants with mild to advanced vision loss at the time of the first administration took part in the clinical trial program. A statistically significant and clinically meaningful difference was observed in phase III clinical trial between patients (n = 21) and control groups (n = 10) in 1 year involvement. Over 100-fold improvement was revealed in the original patients group after 1 year. Evaluation by means of the bilateral multi-luminance mobility testing (MLMT) over the follow-up interval of minimum 1 year from the time of administration, determined that 93% (27 of 29) of all phase III trial patients took improvement in their vision function. The luxturna administration does not cause harmful immune responses. Spark announced a list price of \$850,000 per patient, \$425,000 per eye depending on the treatment ([@B183]; [@B71];[@B182]).

Patisiran (Onpattro) {#s2_14}
--------------------

With the brand *name of* Onpattro, Patisiran is the only FDA-approved RNA interference (RNAi) drug targeting polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR) ([@B7]). The FDA approved this targeted RNA-based drug on August 10, 2018. Alnylam Pharmaceuticals, Inc. (Nasdaq), the leading RNAi therapeutics company, developed this lipid complex drug to treat familial amyloid polyneuropathy (FAP) in adults ([@B217]).

FAP, also known as hereditary transthyretinamyloidosis is caused by mutations in the gene encoding transthyretin (TTR), and is an autosomal dominant, progressive, multi systemic and life-threatening disease. In hereditary transthyretin amyloidosis, both wild and mutant-type transthyretin accumulate as amyloid in peripheral nerves, heart, kidney, and gastrointestinal tract giving rise to polyneuropathy and cardiomyopathy. Neuropathic alterations results in intense sensorimotor disruption with failure of daily life activities and ambulation ([@B77]; [@B161]).

Patisiran is a lipid nanoparticle containing an RNAi targeting the transthyretin mRNA. Once Patisiran enters the cell, transthyretin mRNA is cleaved by the RNAi leading to a decrease in circulating transthyretin protein. This reduces the amyloid accumulations which are linked to transthyretin-mediated amyloidosis ([@B33]). Administrated Patisiran targets primarily the liver. Nucleases cut Patisiran to nucleotides of various lengths ([@B196]). Vitamin A deficiency is reported to be a main risk of Patisiran use by patients ([@B117]).

In an early clinical trial, abnormal transthyretin protein production rapidly diminished dose-dependently ([@B6]). Due to the phase II clinical trial results, Onpattro reduced the level of abnormal transthyretin protein by over 80%. The results also indicated that Patisiran improved neurological symptoms in all 27 patients for more than 24 months ([@B196]). The outcomes of a phase III clinical trial revealed that Onpattro treatment lowered the abnormal transthyretin protein levels and improved FAP-related symptoms as well as the quality of life as compared with placebo groups ([@B8]).

Zolgensma (Onasemnogene Abeparvovec) {#s2_15}
------------------------------------

Recently, AveXis a drugmaker owned by pharmaceutical giant Novartis, developed Onasemnogene Abeparvovec with the brand name of Zolgensma. It is the most recent authorization gene therapy drug by USA FDA (May 2019). It was previously well-known with compound name AVXS-101. Zolgensma is a proprietary gene therapy strategy for the cure of pediatric patients less than 2 years of age which have mutations in both alleles of *SMN1* gene. Zolgensma has been designed to render a healthy copy of SMN gene to seize disease progression through maintenance of SMN gene expression with a single, one-time intravenous infusion ([@B168]; [@B212]; [@B137]; [@B142]).

This drug is a non-replicating recombinant AAV9 containing a functional copy of human SMN1 gene under the control of CMV enhancer/chicken-β-actin-hybrid promoter (CB) to express SMN1 in motor neurons of SMA patients. The unique AAV9 capsid is capable to cross the blood-brain barrier allowing efficient CNS delivery by intravenous administration. The modification of the AAV ITR produces a self-complementary DNA molecule that forms a double-stranded transgene which enhances active transcription ([@B168]; [@B212]).

The efficacy of Zolgensma in SMA patients with bi-allelic *SMN1* gene mutations was investigated in several clinical trials such as STR1VE (NCT03306277) and START (NCT02122952). Bi-allelic *SMN1* gene depletion, two wild type copies of the *SMN2* gene region, as well as lack of the c.859G \> C mutation in exon 7 of *SMN2* gene was confirmed in all participants. 21 patients (mean age of 3.9 months) enrolled at the ongoing clinical trial of STR1VE. All the patients received 1.1 × 10\[1\]\[4\] vg/kg of Zolgensma drug. Comparing results from the clinical study to accessible natural history data of participants with infantile-onset SMA renders initial evidence of the effectiveness of Zolgensma. The next clinical trial involving 15 patients was named START and involved a low-dose cohort of 3 patients with the mean age of 6.3 months and 12 patients in a high-dose cohort with the mean age of 3.4 months. The low-dose cohort received approximately one-third of the dosage of drug as the high-dose cohort. Comparing results from low- and high-dose cohorts showed a dose-response relationship that provides the clinical use of Zolgensma. ([@B10]; [@B64])

Elevated liver enzyme of aminotransferases has been reported with Zolgensma therapy. For patients with impaired liver function it is recommended to examine hepatic aminotransferases \[aspartate aminotransferase (AST) and alanine aminotransferase (ALT)\], total bilirubin and prothrombin before drug infusion. Transient decrease in platelet counts (considered as thrombocytopenia criteria) were revealed at different time points after Zolgensma infusion. Thus, monitoring platelet counts before Zolgensma use and on a regular basis eventually is recommended. Also, transient elevated cardiac troponin-I levels were reported following drug infusion in clinical studies. However, the clinical value of these findings is still unclear ([@B137]).

The drug also carries a heavy price tag of more than \$2.125 million for a one-time treatment which it is the most expensive gene therapy on the market, yet relative cost-effective.

Human Cell-Based Gene Therapy Products {#s3}
======================================

Strimvelis (GSK-2696273) {#s3_1}
------------------------

Adenosine deaminase (ADA) deficiency is considered as an autosomal recessive genetic disease causing the severe combined immune deficiency (SCID). ADA enzyme deficiency is the most widespread kind of the SCID accounting for 15% of all patients ([@B108]). Affected Patients suffer from different metabolic disorders and life-threatening opportunistic infections caused by severe immune deficiency and lymphopenia ([@B213]). Current therapeutic approaches consist of hematopoietic stem cell transplantation (HSCT), Enzyme replacement therapy (ERT) as well as gene therapy tool.

HSCT from a matched sibling donor will be curative by permanently increasing the overall survival (86%) ([@B107]); however, such a donor is available for about 30% of the patients ([@B201]). In the case of matched unrelated (66%) or haploidentical (43%) donors, less survival will be achieved ([@B107]). The other treatment choice is ERT with PEG-ADA which can offer disease relief to the patients but is not a curative method and requires multiple administrations ([@B26]). Gene therapy has provided promising treatments for patients affected by ADA-SCID. Gene therapy attempts for ADA-SCID treatment started in early 1990, when the first gene therapeutic trial was carried out at the NIH Clinical Center using gamma-retroviral mediated gene delivery to the autologous peripheral blood lymphocytes of a 4-year-old ADA-SCID affected girl ([@B80]).

In 2016, the EC approved the GlaxoSmithKline (GSK) stem cell based *ex vivo* gene therapy as a therapeutic option for ADA-SCID. The gene therapy product, also named Strimvelis (GSK2696273), was initially evolved by the San Raffaele Telethon Institute. The manufacturing procedure from HSC transduction to the medicine infusion requires expertise and high standards in product management and, for the time being, is only administered at the San Raffaele Hospital in Milan ([@B9]). Strimvelis consists of autologous hematopoietic stem/progenitor (CD34+) enriched cells transduced *ex vivo* with a retroviral delivery system to express the functional human adenosine deaminase (ADA) cDNA sequence which can replace the enzyme deficiency. At least 4 million purified CD34+ cells/per/kg are required to produce Strimvelis and it is indicated to treat ADA-SCID patients without matched related donor. According to the manufacturer's recommendation, the optimum dose range of Strimvelis (2-20 million CD34+ cells/per/kg) should be administered only once to achieve the best outcome ([@B3]). Prior to autologous infusion of the gene-transduced CD34+ cell, pre-conditioning with low dose Busulfan (an anti-neoplastic alkylating agent) is necessary ([@B50]). The CD34+ enriched cells will be transduced with retroviral vectors encoding the human ADA cDNA and similar to other retroviral-based gene therapy methods, the potential integration mediated mutagenesis needs to be considered ([@B50]).

In a phase I/II trial, Strimvelis drug was evaluated on totally 18 ADA‐SCID children. Evidence of increased immunoglobin production and increased T cell subtypes (CD3+, CD4+ and CD8+) indicated that Strimvelis infusion can promote both cellular and humoral immunity. Gene modified blood cells were stably present in circulation of treated patients in the post gene therapy phase. Increased ADA enzyme activity and consequent decline in dAXP (metabolite accumulated in AD deficiency) demonstrated the gene therapy engraftment in treated patients ([@B50]). Following gene therapy, the most commonly observed adverse effects were upper respiratory infections, gastroenteritis as well as rhinitis among the others, with the highest incidence occurring over the time span between pre-treatment up to 3 months into the treatment. Fortunately, no leukemic transformation was observed in the following 13 years ([@B51]).

Zalmoxis (Allogenic T cells encoding LNGFR and HSV-TK) {#s3_2}
------------------------------------------------------

The allogenic HSCT remains the main therapeutic option for the high risk hematopoietic malignancies. Meanwhile, in the case of haploidentical HSCT, it may end up in failure due to Graft Versus Host Disease (GVHD) ([@B131]). To prevent GVHD in haploidentical HSCT, one option is T cell depletion prior to transplantation which may lead to poor survival due to a severe delay in immune reconstitution ([@B52]). The MolMedproduct, called Zalmoxis, made it possible to overcome this limitation. The partially-matched donor T cells will be modulated genetically to express HSV-TK (thymidine kinase enzyme) as an inducible suicide gene. In the case of GVHD initiation, the engineered transplanted T cells can be targeted and killed *via* administration of the pro-drug Ganciclovir (GCV), which is activated to a toxic triphosphate form by HSV-TK enzyme ([@B70]).

Zalmoxis contains genetically-modified allogeneic T cells using a retroviral delivery system expressing a shortened human low affinity nerve growth factor receptor (ΔLNGFR) and HSV-TK Mut2 to transduce the allogeneic T immune cells. ΔLNGFR expression cassette was used as the selection marker of the transduced manipulated T cells and the HSV-TK Mut2 expression provides the suicide gene induction if necessary. Infusion of the genetically manipulated donor T cells to HSCT (T cell depleted) transplant patients can simply reconstitute the immunity to protect from infections and confront cancer cells; however, donor cells can potentially target the host cells leading to GVHD. In this case, suicide gene induction by GCV administration can kill the donor T cells expressing HSV-TK and GVHD control ([@B150]; [@B154]).

The producer recommended the dose of 1 ± 0.2 × 10^7^ cells/kg for the infusion, following 21-49 days after transplantation, without GVHD. The infusion should be repeated monthly up to 4 months to reach the ≥100 T cell count/µl. The Zalmoxis is not allowed to be administrated in participants younger than 18 years age or in the case of T cell ≥100/µl in circulation ([@B2]).

The application of the Zalmoxis as adjutant treatment of leukemia patients in T cell depleted haploidentical stem-cell transplantation was evaluated in a phase I--II clinical trial (NCT00423124). Briefly, totally 28 participants were infused serially with 0.9-40 × 10^6^ cells/kg of genetically modified purified donor T cells expressing TK after transplantation monthly up to a maximal point of four infusions. As many as 22 participants obtained immune reconstitution (CD3 + counts ≥100 cells/μl) 23 days (13--42) following the infusion, wile10 ones evolved acute GVHD (grade I--IV) while one was reported to have chronic GVHD, which was managed by suicide gene induction. The most common adverse effect of TK cell infusion was acute GVHD. Altogether; these findings indicated that Zalmoxis can enhance the immune system reactivation following T cell depleted HSCT, with controllable GVHD ([@B52]).

Engraftment of the TK positive allogenic donor T cell can activate the host thymopoesis with elevated systemic IL-7 (early maturation of T-cell cytokine), providing a high number of newly generated TK-negative naive lymphocytes. This finding suggests that even after suicide gene induction and TK-positive T cell elimination to control GVHD, long-term immune reconstitution will reduce the risk of infection after HSCT (no infection was recorded in treated patient of TK007 after 166 days) ([@B207]). Consistently, results published from the phase III clinical trials (TK008, NCT00914628) carried out in Europe and United States revealed that infusion of genetically engineered allogenic T cells (MM-TK) (1\*107/kg up to four monthly infusions) can increase the 1-year-disease-free survival by 22% in patients (30% vs 52%) ([@B25]).

Analysis of 36 individuals treated with Zalmoxis in different trials (22 patients from TK007 trial and 14 patients from the ongoing phase III TK008 trial) and 127 control patients, demonstrated 1 year overall survival (OS) (40% vs 51%, p = 0.03) in those patients who survived relapse-free 3 weeks post transplantation. Nevertheless, the relapse probability and leukemia free survival were not significantly different([@B2]).

Zalmoxis can provide promising curative improvements for HSCT patients when the matched donor is not available. It can benefit the patients in different aspects including post-transplant GvHD control, Graft versus Leukemia (GvL) improvement and relapse decrease as well as more important long term immune reconstitution leading to reduced infection probability and mortality.

Kymriah (Tisagenlecleucel) {#s3_3}
--------------------------

In 2012, Novartis drugmaker, in collaboration with the University of Pennsylvania, began to study chimeric antigen receptor T-cell (CAR T) therapies for acute lymphoblastic leukemia (ALL) treatment. The first approved CAR T-cell-based gene therapy by United States FDA (August 2017) was kymriah (tisagenlecleucel, Novartis Pharmaceuticals, co), which is used for the treatment of children and young adult patients (up to 25 years old) with relapsed B-cell ALL. ALL is the most common malignant tumor diagnosed in children ([@B19]) and the second most common acute leukemia in adults ([@B199]). Despite the advances in common therapeutics of chemotherapy or stem cell transplantation, the relapsed or refractory leukemia still remains a clinical challenge ([@B115]).

CAR is an engineered receptor exposing extracellular cancer-specific epitopes (scfv region) linked to the transmembrane and intracellular TCR derived and stimulatory domains. Four generations of CAR T-cells have been developed up to now with different cancer-killing efficiencies and cytokine releasing abilities ([@B190]). The scfv antibody domain connects to the target antigen in an MHC independent manner leading to CAR clustering and activation of T-cell through intracellular region composing the TCR-derived CD3ζ chain, without (first generation) or with co-stimulatory domains of the CD28 (generations 3 and 4), OX40/4-1BB (TNF/NGF family, generation 3). The 4th generation of CART proves more effective in solid tumors elimination, also known as TRUCK cells which are induced for secretion of cytokines (IL-12) in target tissue for augmentation of the t cell response and host innate immunity activation for elimination of antigen negative cancer cells ([@B44]; [@B43]). The clinical efficacy depends on the durable persistence of CAR T-cells assured by co-stimulatory signals protecting the CAR T-cells from 'activation induced cell death' (long term). More importantly, the activated CAR T-cells render target-specific memory cells which it induces inhibiting tumor relapse. The CAR T-cell has been clinically used in leukemia and lymphoma ([@B106]); this is while, clinical trials have shown that it is also applicable to kill solid tumors ([@B179]). While enjoying approved clinical efficacy, CAR T-cells therapy causes side effects including on-target off-organ toxicity, cytokine release syndrome (CRS), neurotoxicity, auto-reactivity and other common reactions associated with antibody therapeutic like fever, nausea, and hypotension ([@B5]).

Kymriah is composed of autologous T cells suspension that are genetically manipulated with a lentiviral delivery system to produce a CAR comprising of a murine single-chain antibody fragment (scFv) specific for CD19 joint to an intracellular cytoplasmic domain for 4-1BB (CD137) and CD3 zeta with a CD8 transmembrane hinge. The autologous T cells is transduced with a self-inactivating lentiviral vector pseudo-typed with a VSV-G envelope derived from HIV-1 genome in ex-vivo condition. The vector will be integrated into the genome of transduced cells and will result in production of the tisagenlecleucel CAR under the regulation of a constitutively active promoter. After binding to target cells (CD19 expressing cells), the activated tisagenlecleucel CAR will initiate the antitumor activity through CD3 domain. The intracellular 4-1BB costimulatory domain will augment the antitumor reaction and also ensures durable persistence of the CAR T-cells ([@B4]; [@B204]).

As part of safety concerns to avoid replication competent retrovirus (RCR) during Kymriah manufacturing, all needed HIV-1 helper sequences and the pseudo-typed VSV-G envelope sequences are distributed among different constructs with minimum sequence homology, which ensures limited RCR. Moreover, the RCR formation will be checked in the peripheral blood samples of treated patients using VSV-G qPCR ([@B204]). The recommended dosage depends on body weight: 0.2-5 x 10^6^ CAR-positive viable T cells per kg for \<50kg individuals or 0.1-2.5 x 10^8^ per kg for \>50kg cases. Similar to other CAR T products, it should be infused after completion of the lympho-depleting chemotherapy ([@B4]).

In a phase II trial, the efficacy of Kymriah was evaluated in 63 pediatric or young patients with relapsed B-cell ALL. The results showed that 81% of patients represent overall remission with no minimal residual disease. The remission was durable with overall survival of 90% for 6 months and 76% after 1 year. The Kymriah was persisted in patients' blood as long as 20 months. The cytokine release syndrome was observed in 77% of patients ([@B139]). Kymriah was successful in treatment of adult patients with diffused large B-cell Lymphoma (DLBCL), the dominant form of lymphoma. In this global phase II trial, as many as 99 patients (22-76 years old) were infused with Kymriah, formerly CTL019, which resulted in 95% of complete remission in 3 months, sustained at 6 months. The CTL019 was persisted in blood of patients for up to 367 days and CRS was observed in 58% of treated patients ([@B186]).

Yescarta (AxicabtageneCiloleucel) {#s3_4}
---------------------------------

In October 2017, Yeskarta (Axicabtageneciloleucel, Axi-Cel, Kite Pharma, Inc), another CAR T-cell therapy was approved by USA FDA for the treatment of adult patients suffering from aggressive non-Hodgkin lymphoma with the history of at least two failed systemic therapies. DLBCL is the dominant subtype of blood malignancies with a wide range of clinical and genetic heterogeneity ([@B19]). The majority of DLBCL new cases respond to a standard care therapy consisting of rituximab and chemotherapy; however, approximately 10--15% of them experience a refractory state ([@B177]). According the FDA, Yescarta can be administrated in the case of DLBCL, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma and DLBCL resulting from follicular lymphoma ([@B1]).

Yescarta is a CD19-directed ex-vivo modulated autologous T cells transfected with gamma-retroviral vector. It expresses a CAR consisting of an extracellular murine anti-CD19 single-chain variable fragment fused to a cytoplasmic domain comprising of CD28 and CD3-zeta co-stimulatory domains. The autologous T-cells harvested from patients by leukapheresis would be shipped to legal centers. The transferred T-cells are then enriched in a closed system in the Yeskarta manufacturing center. The activated T-cells (by anti-CD3 and IL-2 treatment) would be transduced with a retroviral vehicle expressing the anti-CD19 CAR gene. Finally, following less than 10 days for manufacturing processes, the Yeskarta CAR T-cell is ready for infusion back into the patient ([@B177]).

The genetically manipulated autologous CAR T cells can target and eliminate CD19-positive cells when infused back into the patient. 2 × 10^6^ CAR-positive viable T cells per kg body weight is recommended dose which is administrated following a lymphodepleting chemotherapy. It is not designate for the cure of patients with primary CNS lymphoma ([@B1]).

In a phase II trial, 101 patients received Yeskarta and the result indicated an 82% objective response rate and a 54% complete response rate with a 52% overall rate of survival within 18 months. The common observed side effects were neutropenia (78%) and anemia (43%) ([@B130]; [@B156]). The Zuma-1 results showed approximately six-fold higher complete remission rates when compared to the achievements of the SCHOLAR-1, the benchmark multi-cohort retrospective study on refractory DLBCL patients outcomes ([@B155]).

Invossa (TissueGene-C) {#s3_5}
----------------------

Invossa (TissueGene-C) has completed phase III trials in the USA and attained marketing approval in Korea by KolonTissueGene as a first-in-class cell mediated gene therapy strategy for the treatment of symptomatic and persistent knee osteoarthritis (OA). It contains 3:1 mixture ratio of non-transformed and retrovirally transduced allogenic chondrocytes that upregulate transforming growth factor β1 (TGF β1) ([@B122]).

Since the beginning of 2015, application of the Invossa progressed rapidly through its clinical trials and commercialization in the USA. To assess the safety and efficacy of Invossa, several phase II and III clinical trials and also post marketing surveillance studies were completed or recruited in Korea and USA. Studies showed that Invossa treatment can improve knee OA significantly ([@B41]). In another phase II clinical trial on patients with a confirmed diagnosis of knee OA, Invossa treatment improved pain, sport activities and quality of daily life ([@B45]). Additionally, in the randomized double blind, multi-center, placebo-controlled phase III trial on 156 patients with confirmed knee OA, Invossa treatment successfully improved the quality of patients' lives ([@B46]). In the most recent phase III clinical trial on 163 OA patients, Invossa significantly improved the function and pain relief with structural refinement and mild to severe adverse effects. The most frequent side effects in the Invossa are reported as peripheral edema, arthralgia, joint swelling, and injection-site pain ([@B122]).

Finally, KolonTissueGene achieved medical product approval of Invossa in July 2017. A post-marketing surveillance of Invossa injection in patients with OA is now involving to evaluate the safety and effectiveness of this new drug. What's more, several studies have investigated the underlying molecular mechanisms in the effectiveness of Invossa on OA. The majority of studies suggest that Invossa provides an anti-inflammatory surroundings in the arthritic knee joints by means of macrophage polarization which is crucial for modifying the disease ([@B47]; [@B124]).

Timeline and the Future Trend of Gene Therapy Market {#s3_6}
----------------------------------------------------

In 1998, Vitravene was the first clinic antisense gene therapy product for the treatment of CMV retinitis in HIV-infected patients that was approved by USA FDA ([@B65]). For targeting HNSCC, a common form of cancer in China, Gendicine was approved in 2003. It is a recombinant human adenovirus expressing Tp53 gene, which entered the Chinese market in 2004 ([@B159]; [@B160]). Also in 2004, Macugen was approved by USA FDA as the first therapeutic RNA treatment of AMD ([@B100]). Oncorine is the second approved gene therapy drug in China which is used for cancer treatment ([@B128]). The next gene therapy drug targeting pancreas cancer is Rexin-G which was approved by USA FDA in 2007 ([@B98]). Neovasculgen gene therapy drug is only developed and approved for Russian market in 2012 ([@B69]). Europe approved their first gene therapy drug, Glybera, in 2012 to treat LPLD. Glybera is nowadays not anymore listed on its developer company product pipeline ([@B104]). Kynamro is another antisense drug inhibiting apoB in HoFH patients which was approved by USA FDA in 2013 ([@B166]; [@B140]; [@B193]; [@B200]). Imlygic was approved by the USA FDA for targeting melanoma in 2015 ([@B169]; [@B163]; [@B35]). As the tenth clinical gene therapy product, Exondys51 was approved by USA FDA in 2016 for treatment of DMD patients ([@B203]; [@B12]). Spinraza as the first gene therapy to treat SMA patients was approved by USA FDA in 2016 and by EMA in 2017 ([@B90]). Defibrotide was developed to treat patients with hepatic SOS/VOD prior to HSCT and was approved by USA FDA in March 2016 ([@B173]). In 2016, Strimvelis, was approved in Europe a gene therapy for treating ADA-SCID patients. 2017 was promising year for stem cell based gene therapy ([@B108]), ([@B213]). The United States finally approved *ex vivo* CAR-T therapies. Kymriah is considered the first CAR-T therapy targeting ALL which was approved by USA FDA in August of 2017. As second CAR-T therapy product, Yescarta, treating adult patients with diffuse large B-cell lymphoma, was approved by USA FDA in October of 2017 ([@B177]; [@B199]). Zalmoxis and Invossa are stem cells based gene therapy products than entered the clinic in 2016 and 2017 respectively ([@B131]) ([@B122]). Spark Therapeutics has been granted an FDA approval for their Luxturna gene therapy drug in 2018. This pharma company utilizes an AAV system to deliver RPE65 gene into the patients eye suffering from retinal dystrophy caused by RPE mutations ([@B167]). *As the first RNAi* drug, Patisiran was approved by FDA in 2018 ([@B7]). In May 2019, Zolgensma was approved by USA FDA as the twentieth approved gene therapy products until now ([**Figure 2**](#f2){ref-type="fig"}). Finally, at the beginning of 2019, Zaynteglo, also known as Lentiglobin got conditional approval by EMA for beta thalassemia. Furthermore, BMN 270 a drug for hemophilia A, and GT-AADC a product for AADC deficiency are two highlighted gene therapy products that may be approved until 2020.

![Distribution countries of approval gene therapy drugs **(A)** and timeline of gene therapy development **(B)**. As it is shown the North America and Europe are main parts of the gene therapy development and market **(A)**. Gene therapy market began with approval of Vitravene drug in 1998, and it was continued with approval of Zolgensma drug in 24 May, 2019. 2016 and 2017 years were promising points in gene therapy market since near 10 gene therapy products such as Imlygic, Defibrotide, Spinraza, Zalmoxis, Exondys51, Strimvelis, Invossa, Yeskarta and Kymriah were approved by relevant authority **(B)**.](fgene-10-00868-g002){#f2}

[**Table 2**](#T2){ref-type="table"} summarized more gene therapy clinical trials that are currently ongoing for advanced stages of trials and/or approval.

###### 

Highlighted ongoing gene therapy products.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Product name                                       Developer/\                                 Structure and mechanism\                                                                                                                                                                                                                                            Therapeutic indication and target tissue                                                                                                                                         Clinical trials ID
                                                     sponsor                                     of action                                                                                                                                                                                                                                                                                                                                                                                                                                            
  -------------------------------------------------- ------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------
  Zynteglo\                                          Bluebird Bio                                *Ex vivo* transplantation of hematopoietic stem cells manipulated by a lentiviral vehicle transferring HBB                                                                                                                                                          Beta thalassemia\                                                                                                                                                                NCT01745120\
  (Lentiglobin BB305)                                                                                                                                                                                                                                                                                                                                                (*conditional approved by EMA*)                                                                                                                                                  NCT02151526\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT03207009\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT02140554\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT02906202\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT03207009

  BMN 270\                                           BioMarin Pharmaceutical                     An AAV vector transferring factor VIII in hemophilia A individuals with Residual FVIII Levels ≤ 1 IU/dl                                                                                                                                                             Hemophilia A                                                                                                                                                                     NCT03392974\
  (Valoctocogene roxaparvovec)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        NCT03370913\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT02576795\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT03520712

  AAV2-hAADC                                         PTC Therapeutics                            AAV serotype 2 expressing human AADC (hAADC)                                                                                                                                                                                                                        Aromatic L-amino Acid Decarboxylase\                                                                                                                                             NCT02926066\
                                                                                                                                                                                                                                                                                                                                                                     (AADC9 deficiency\                                                                                                                                                               NCT02852213\
                                                                                                                                                                                                                                                                                                                                                                     AADC                                                                                                                                                                             NCT02399761\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT02926066\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT01395641

  Lenti-D                                            Bluebird Bio                                *Ex vivo* Transplantation of CD34+ stem cells manipulated by lentiviral vector to contain a functional ABCD1 gene                                                                                                                                                   Cerebral adrenoleukodystrophy (CALD), ABCD1 gene                                                                                                                                 NCT03852498\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT01896102\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT02698579

  NSR-REP1\                                          Spark Therapeutics\                         An AAV2 vector transferring REP1 gene into the eye. The drug is delivered surgically by injection into the sub-retinal space                                                                                                                                        Retinal Gene Therapy for choroideremia                                                                                                                                           NCT02553135\
  (AAV2-hCHM)                                        Nightstar Therapeutics                                                                                                                                                                                                                                                                                                                                                                                                                                                                           NCT02077361\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT03507686\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT03496012\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT01461213\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT03584165

  ADVM-043\                                          Adverum                                     An AAV expressing Alpha-1 Antitrypsin (A1AT) gene to patients with A1AT deficiency                                                                                                                                                                                  A1AT Deficiency                                                                                                                                                                  NCT02168686\
  (AAVrh.10hA1AT)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NCT03804021

  LYS-SAF302                                         Lysogene, Regenxbio, Sarepta Therapeutics   AAVrh10 virus expressing N-sulfoglucosamine sulfohydrolase (SGSH)                                                                                                                                                                                                   Sanfilippo type A syndrome                                                                                                                                                       NCT03612869\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT02746341

  AMT-061                                            uniQure                                     An AAV5 viral vector expressing the Padua variant of Factor IX (FIX-Padua)                                                                                                                                                                                          Hemophilia B                                                                                                                                                                     NCT03569891\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT03489291

  Fidanacogene elaparvovec\                          Pfizer                                      An AAV with engineered capsid that expresses human coagulation factor IX gene                                                                                                                                                                                       Hemophilia B                                                                                                                                                                     NCT03587116\
  (SPK-9001)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          NCT03307980

  OTL-103 (GSK2696275)                               Orchard Therapeutics                        *Ex vivo* autologous transplantation of hematopoietic stem cells manipulated by a lentiviral vehicle expressing WAS gene                                                                                                                                            Wiskott Aldrich syndrome                                                                                                                                                         NCT01515462\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT03837483

  OTL-200 (GSK2696274)                               Orchard Therapeutics                        *Ex vivo* autologous transplantation of CD34+ stem cells manipulated by lentiviral vector\                                                                                                                                                                          Metachromatic Leukodystrophy (MLD)                                                                                                                                               NCT03392987
                                                                                                 expressing human arylsulfatase A (ARSA) gene                                                                                                                                                                                                                                                                                                                                                                                                         

  Instiladrin\                                       FKD Therapies, Ferring Pharmaceuticals      Nonreplicating recombinant adenovirus type 5 expressing interferon alpha-2b (IFNα2b) gene, fused with the excipient Syn3 (rAD-IFN/Syn3)                                                                                                                             Bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle invasive bladder cancer (NMIBC)                                                                                            NCT02773849
  (rAd-IFN/Syn3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  OTL-101                                            Orchard Therapeutics                        Lentiviral transduced CD34+ cells to express ADA gene                                                                                                                                                                                                               Adenosine deaminase severe combined immune deficiency (ADA-SCID)                                                                                                                 NCT03765632

  RT-100\                                            Renova Therapeutics                         AAV5 vehicle expressing human adenylyl cyclase type 6 which it is directly injected throughout cardiac catheterization into the arteries feeding the heart                                                                                                          Heart failure and reduced ejection fraction                                                                                                                                      NCT03360448\
  (Ad5.hAC6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          NCT00787059

  ADXS11-001\                                        Advaxis                                     Targeted immunotherapy\                                                                                                                                                                                                                                             Metastatic cervical cancer                                                                                                                                                       NCT02853604\
  (Axalimogene filolisbac)                                                                       /attenuated Listeria monocytogenes manipulated for secretion of antigen/adjuvant fusion proteins                                                                                                                                                                                                                                                                                                                                                     NCT02002182\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT02164461

  OXB-301\                                           Oxford BioMedica                            An attenuated engineered vaccinia virus Ankara that delivers the 5T4 oncofetal antigen gene to stimulate the immune cells against cancer cells                                                                                                                      Ovarian cancer, colorectal cancer                                                                                                                                                NCT01556841\
  (MVA-5T4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           NCT01569919

  Pexa-Vec\                                          SillaJen, Transgene                         Wyeth strain vaccinia virus engineered to directly lyse tumor cells and stimulate anti-tumor immunity                                                                                                                                                               Hepatocellular carcinoma                                                                                                                                                         NCT02562755\
  (JX-594)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            NCT03071094

  SPK-8011                                           Spark Therapeutics                          Manipulated AAV vehicle (to specifically transfer the human factor VIII (hFVIII) gene into liver                                                                                                                                                                    Hemophilia A                                                                                                                                                                     NCT03003533 NCT03432520\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT03876301

  Toca 511 and Toca FC (vocimagene amiretrorepvec)   Tocagen, ApolloBio                          Toca 511 is a retroviral vector expressing cytosine deaminase. Toca FC is prodrug 5-fluorocytosine which is converted into 5-fluorouracil by CD                                                                                                                     Glioblastoma Multiforme\                                                                                                                                                         NCT02414165\
                                                                                                                                                                                                                                                                                                                                                                     And Anaplastic Astrocytoma                                                                                                                                                       NCT02576665\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT02598011

  VB-111\                                            Vascular Biogenics                          Targeted anticancer gene-based biologic administered as an IV infusion once every 2 months. VB-111 was developed through VBL's Vascular Targeting System (VTS™). VBL says the mechanism combines blockade of tumor vasculature with an anti-tumor immune response   Solid tumors, including recurrent platinum-resistant ovarian cancer                                                                                                              NCT03398655
  (ofranergene obadenovec)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  VGX-3100                                           Inovio Pharmaceuticals                      A synthetic DNA vehicle targeting the E6 and E7 proteins of HPV types 16 and 18, also is considered as a DNA vaccine                                                                                                                                                Cervical high-grade squamous intraepithelial lesion infected by HPV subtypes of 16 and 18                                                                                        NCT03185013\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT03721978\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT03603808\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT03499795\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT03180684.

  VM202                                              ViroMed                                     DNA vehicle expressing two isoforms of hepatocyte growth factor, HGF728 and HGF723                                                                                                                                                                                  Painful diabetic peripheral neuropathy, Chronic nonhealing ischemic foot ulcer in diabetes, Critical limb ischemia, Amyotrophic lateral sclerosis, Acute myocardial infarction   NCT02563522\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT02427464\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT03363165\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT03404024

  QTA020V                                            Astellas                                    A rAAV transfects retinal ganglion cell to express BDNF and one of its receptors (TrkB) resulting reduction in cell death                                                                                                                                           Glaucoma                                                                                                                                                                         --

  EB-101                                             Abeona Therapeutics                         This drug was designed to transfer a healthy copy of COL7A1gene using the patients' own skin cells                                                                                                                                                                  RDEB (skin disease)                                                                                                                                                              NCT01263379

  AT132                                              Audentes Therapeutics                       An AAV8 vector containing a functional copy of the MTM1 gene                                                                                                                                                                                                        X-Linked Myotubular Myopathy (ASPIRO)                                                                                                                                            NCT03199469

  NSR-RPGR                                           Biogen/Nightstar                            An AAV8 encoding retinitis pigmentosa GTPase Regulator (RPGR)                                                                                                                                                                                                       X-linked retinitis pigmentosa (XLRP)                                                                                                                                             NCT03116113

  Generx\                                            Angionetics, Huapont Life Sciences          A human serotype 5 adenovirus that express fibroblast growth factor-4 (FGF-4) gene                                                                                                                                                                                  Angina, Stable                                                                                                                                                                   NCT02928094\
  (Ad5FGF-4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          NCT01550614\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT00346437

  GS010                                              GenSight Biologics                          AAV2 vector that expresses the human wild-type ND4 protein                                                                                                                                                                                                          Leber Hereditary Optic Neuropathy (LHON) caused by mutation of the ND4 gene                                                                                                      NCT02652780\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT02652767\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT03293524\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NCT03406104
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In recent years a number of gene therapies based on gene editing tools, especially CRISPR system, advanced to human clinical trial stage. Gene editing technologies including CRISPR, Zinc Finger Nuclease (ZFN) and TALEN allow scientists to undertake precise genomic modifications at desired human genome positions yielding tremendous beneficial results in modern medicine and the field of genetics. Ongoing human gene therapy trials based on gene editing systems are listed in [**Table 3**](#T3){ref-type="table"}. The upcoming trials mark the maturation of the gene editing tools into a clinical-grade technology.

###### 

Recruited clinical trials based on genome editing technologies (e.g. CRISPR/Cas, ZFN and TALEN).

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Product name                                                                        Developer/\                                                   Structure and mechanism of action                                                                                                                                                                                                         Therapeutic indication and target tissue     Clinical trials ID
                                                                                      sponsor                                                                                                                                                                                                                                                                                                                                              
  ----------------------------------------------------------------------------------- ------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------- --------------------
  AGN-151587\                                                                         Allergan                                                      An AAV5 vector employed in EDIT-101 contains two gRNAs and Cas9 to correct IVS26 mutation in CEP290 gene                                                                                                                                  Leber Congenital Amaurosis 10 (LCA10)        NCT03872479
  (EDIT-101)                                                                                                                                                                                                                                                                                                                                                                                                                               

  Cyclophosphamide\                                                                   Sichuan University                                            *Ex vivo* gene manipulation of T cells with CRISPR/Cas system to target non-small cell lung cancer                                                                                                                                        Metastatic NSCLC                             NCT02793856
  (PD-1 Knockout T Cells)                                                                                                                                                                                                                                                                                                                                                                                                                  

  PD-1 Knockout T Cells                                                               Yang Yang                                                     *Ex vivo* gene manipulation of Peripheral blood lymphocytes with CRISPR/Cas system to knockout PD1 gene. Then EBV-CTL will be produced (PD-1 Knockout EBV-CTL)                                                                            Advanced-stage EBV-associated malignancies   NCT03044743

  PD-1 Knockout T Cells                                                               Hangzhou Cancer Hospital                                      *Ex vivo* gene manipulation of T cells with CRISPR/Cas system to target esophageal cancer                                                                                                                                                 Esophageal Cancer                            NCT03081715

  CTX001                                                                              Vertex Pharmaceuticals Incorporated                           Autologous CD34+ Hematopoietic Stem and Progenitor Cells (hHSPCs) manipulated with CRISPR/Cas9 system at the enhancer position of the BCL11A gene leads to increase in fetal hemoglobin                                                   Hematologic diseases (Hemoglobinopathies)    NCT03655678\
                                                                                                                                                                                                                                                                                                                                                                                                                                           NCT03745287

  SB-FIX                                                                              Sangamo Therapeutics                                          An AAV2/6 virus with ZFN inserting Factor 9 gene under the control of albumin promoter for liver expression                                                                                                                               Hemophilia B                                 NCT02695160

  ST-400                                                                              Sangamo Therapeutics                                          Autologous Hematopoietic Stem Cell Transplant/ST-400 is composed of the patient's own blood stem cells which are genetically modified with ZFN technology to disrupt a precise and specific sequence of the enhancer of the BCL11A gene   Transfusion Dependent Beta-thalassemia       NCT03432364

  CCR5 gene modification                                                              Affiliated Hospital to Academy of Military Medical Sciences   CD34+ hematopoietic stem/progenitor cells from donor are manipulated with CRISPR/Cas9 aiming CCR5 gene deletion from cell surface                                                                                                         HIV-1-infection                              NCT03164135

  SB-318                                                                              Sangamo                                                       An AAV2/6 viral vehicle combined with ZFN to incorporated IDUA under the control of albumin promoter for liver expression                                                                                                                 MPS I (Hurler syndrome)                      NCT02702115

  SB-913                                                                              Sangamo                                                       An AAV2/6 viral vehicle linked with ZFN tool to incorporated IDS gene under the control of albumin promoter in liver cells                                                                                                                MPS II (Hunter's syndrome)                   NCT03041324

  UCART123                                                                            Cellectis S.A.                                                Allogeneic engineered T-cells with TALEN system expressing anti-CD123 chimeric antigen receptor                                                                                                                                           AML                                          NCT03190278

  UCART019                                                                            Chinese PLA General Hospital                                  CRISPR/Cas9 mediated CAR-T Cells Targeting CD19 in individuals with relapsed or refractory CD19+ leukemia and lymphoma                                                                                                                    leukemia and lymphoma                        NCT03166878

  Anti-Mesothelin CAR-T cells                                                         Chinese PLA General Hospital                                  Knocking out of PD-1 and TCR genes using CRISPR/Cas in CAR T Cells                                                                                                                                                                        Solid Tumor, Adult                           NCT03545815

  NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1   University of Pennsylvania                                    Autologous T cells manipulated with a lentiviral vector for expressing NY-ESO-1 and transfected with CRISPR guide RNA to for knocking out of endogenous TCRα, TCRβ and PD-1 (NYCE T Cells)                                                Multiple Myeloma                             NCT03399448

  Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cewlls                       Chinese PLA General Hospital                                  Using CRISPR/Cas9 to targetCD19 and CD20 or CD22 in CAR-T Cells for treatment of Relapsed or Refractory Leukemia and Lymphoma                                                                                                             Leukemia\                                    NCT03398967
                                                                                                                                                                                                                                                                                                                                                                                              Lymphoma                                     
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Recent advances in understanding molecular mechanism of human diseases and treatment are boosting the global gene therapy market. This market is categorized into cancers, neurological diseases, rare genetic diseases, cardiovascular disorders, and infectious diseases. Cancers and monogenic diseases had the highest market share in recent years respectively. Viral vectors (mainly retrovirus, lentivirus, adeno-associated virus) in comparison to non-viral vectors are the preferred gene therapy vehicles in the clinic. High-efficiency of gene transduction, specific gene delivery and targeting, safety and reduced administration dose are the main benefits of viral vectors. North America and Europe are dominant players and drive advancements in gene therapy market of cancer and rare genetic diseases. Nowadays, the key trends of the gene therapy market are high prevalence of human cancers and genetic disorders, clarifying gene therapy guidelines and rising financial support of gene therapy and cell-based gene therapy in clinical trials. However, safety and efficacy problems, prolonged laboratory procedures for conducting clinical studies, unknown product interactions with host, and high cost of gene therapy drugs are major barriers in the way of gene therapy market.

Conclusion {#s4}
==========

Despite considerable efforts in gene therapy segment, only a few of the twenty approved gene and cell-based gene therapy products were translated into the clinic (May 2019). In the previous year, numerous promising results attested progress in clinical gene therapies for monogenic diseases, inherited blindness, certain inherited neurodegenerative diseases, metabolic genetic disorders and a number of bone marrow and lymph nodes cancers ([@B74]).

Growth and development of viral delivery systems emerge as effective tools for gene manipulation and gene therapy approaches such as CRISPR/Cas has revolutionized the realm of gene therapy ([@B72]; [@B75]).

Although Glybera was withdrawn from the European market in early 2017, approval of six gene therapy and cell-based gene therapy products, known as Invossa, Luxturna, Kymriah, Yescarta, Patisiran, and recently approved Zolgensma (May 2019), promise a new era in gene therapy for untreatable genetic disorders.

As such, the global gene therapy market has grown commensurately in recent years and is expected to grow at a high rate through 2030 according to Grand View Research. A recent report published by Roots Analysis on 'Gene Therapy Market (2nd Edition), 2018-2030', stated that nearly 300 product candidates are currently under various stages of development for a diverse range of applications.
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